发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
INTRODUCTION:Infants born to women living with HIV initiating combination antiretroviral therapy (cART) late in pregnancy are at high-risk of intrapartum infection. Mother/infant perinatal antiretroviral intensification may substantially reduce this risk. METHODS:In this single arm Bayesian trial, pregnant women with HIV receiving standard of care ARV prophylaxis in Thailand (maternal antenatal lopinavir-based cART; non-breastfed infants 4 weeks postnatal zidovudine) were offered 'antiretroviral intensification' (labor single-dose nevirapine plus infant zidovudine-lamivudine-nevirapine for two-weeks followed by zidovudine-lamivudine for two-weeks) if their antenatal cART was ≤8 weeks before delivery. A negative birth HIV-DNA PCR followed by a confirmed positive PCR defined intrapartum transmission. Prior to study initiation, we modeled intrapartum transmission probabilities using data from 3,738 mother/infant pairs enrolled in our previous trials in Thailand using a logistic model, with perinatal maternal/infant antiretroviral regimen and predicted viral load at delivery as main covariates. Using the characteristics of the women enrolled who received intensification, prior intrapartum transmission probabilities (credibility intervals; CrI) with/without intensification were estimated. After including the observed transmission data in the current study, the corresponding Bayesian posterior transmission probability was derived. RESULTS:No intrapartum transmission of HIV was observed among the 88 mother/infant pairs receiving intensification. The estimated intrapartum transmission probability was 2·2% (0·5-6·1) without intensification versus 0·3% (95%CrI 0·0-1·6) with intensification. The probability of superiority of intensification over standard of care was 94·4%. Antiretroviral intensification appeared safe. CONCLUSION:Mother/infant antiretroviral intensification was effective in preventing intrapartum transmission of HIV in pregnant women receiving ≤8 weeks antepartum cART.
展开更多
最新影响因子:3.771 | 期刊ISSN:1525-4135 | CiteScore: |
出版周期:Monthly | 是否OA:YES | 出版年份:1999 |
期刊官方网址:http://journals.lww.com/jaids/pages/default.aspx
期刊投稿地址:http://journals.lww.com/jaids/Pages/informationforauthors.aspx
自引率:9.30% | 研究方向:医学-传染病学 |
出版地区:UNITED STATES |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
JAIDS:《获得性免疫缺陷综合征杂志》试图通过介绍跨所有学科的重要新科学来结束艾滋病毒的流行,从而增进我们对全球艾滋病毒感染的生物学、治疗和预防的理解。 JAIDS:《获得性免疫缺陷综合征杂志》是值得信赖的、跨学科的HIV和aids相关信息资源,重点关注基础和转化科学、临床科学、流行病学和预防。JAIDS由临床病毒学、分子生物学和流行病学领域的顶尖领导者联合编辑,出版关于HIV感染诊断和治疗进展的重要信息,以及在治疗学和疫苗方法开发方面的最新研究。这本开创性的杂志汇集了来自世界各地经过严格同行评审的文章、对当前研究的评审、临床试验结果和流行病学报告。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
IMMUNOLOGY (免疫学) 3区 INFECTIOUS DISEASES (传染病学) 2区 |
49/155 20/88 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
341 | 335 | 6 |
引文计数(2018)
文献(2015-2017)
次引用
篇文献
序号 | 类别 | 排名 | 百分位 |
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
影响因子:1.714
ISSN:1386-2073
研究方向:化学-生化研究方法
影响因子:6.088
ISSN:1933-7213
研究方向:医学-神经科学
影响因子:1.379
ISSN:0362-5664
研究方向:医学-临床神经学
影响因子:4.287
ISSN:1473-7175
研究方向:CLINICAL NEUROLOGY-PHARMACOLOGY & PHARMACY
影响因子:1.821
ISSN:1528-4336
研究方向:医学-传染病学
影响因子:2.385
ISSN:1120-009X
研究方向:医学-药学
影响因子:2.706
ISSN:1076-6294
研究方向:医学-传染病学
影响因子:4.177
ISSN:1178-6973
研究方向:-
影响因子:5.758
ISSN:0305-7453
研究方向:医学-传染病学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 投稿经验
(由下方点评分析获得,2人参与,11808人阅读)